Long-term Safety of Darolutamide Among Patients with Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy

RH Jones; K Fizazi; ND James; TL Tammela; N Matsubara; F Priou; P Beuzeboc; T Lesimple; P Bono; V Kataja; JA Garcia; A Protheroe; J Aspegren; H Joensuu; I Kuss; S Thiele; S Fiala-Buskies; E Vjaters

Long-term Safety of Darolutamide Among Patients with Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy

RH Jones (Corresponding Author), K Fizazi, ND James, TL Tammela, N Matsubara, F Priou, P Beuzeboc, T Lesimple, P Bono, V Kataja, JA Garcia, A Protheroe, J Aspegren, H Joensuu, I Kuss, S Thiele, S Fiala-Buskies, E Vjaters

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	MP27-13
Pages (from-to)	E455-E455
Number of pages	1
Journal	Journal of Urology
Volume	207
Issue number	5 S
Publication status	Published - 14 May 2022
Externally published	Yes
Event	Annual American Urological Association (AUA) Meeting - New Orleans, United States Duration: 13 May 2022 → 16 May 2022 https://www.auanet.org/aua2022 https://www.aua2021.org/attendee-info/aua2022-dates-and-location?AUAID= https://www.eventscribe.net/2022/AUA2022/

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://www.auajournals.org/action/doSearch?AllField=Long-term+Safety+of+Darolutamide+Among+Patients+with+Metastatic+Castration-resistant+Prostate+Cancer+Who+Received+More+Than+4+Years+of+Therapy&ContentGroupKey=10.1016%2Fjuro.2022.207.issue-Supplement_5

Cite this

Jones, RH., Fizazi, K., James, ND., Tammela, TL., Matsubara, N., Priou, F., Beuzeboc, P., Lesimple, T., Bono, P., Kataja, V., Garcia, JA., Protheroe, A., Aspegren, J., Joensuu, H., Kuss, I., Thiele, S., Fiala-Buskies, S., & Vjaters, E. (2022). Long-term Safety of Darolutamide Among Patients with Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy. Journal of Urology, 207(5 S), E455-E455. Article MP27-13. https://www.auajournals.org/action/doSearch?AllField=Long-term+Safety+of+Darolutamide+Among+Patients+with+Metastatic+Castration-resistant+Prostate+Cancer+Who+Received+More+Than+4+Years+of+Therapy&ContentGroupKey=10.1016%2Fjuro.2022.207.issue-Supplement_5

@article{1ca5374c5e0743f6917780ce11684e25,

title = "Long-term Safety of Darolutamide Among Patients with Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy",

author = "RH Jones and K Fizazi and ND James and TL Tammela and N Matsubara and F Priou and P Beuzeboc and T Lesimple and P Bono and V Kataja and JA Garcia and A Protheroe and J Aspegren and H Joensuu and I Kuss and S Thiele and S Fiala-Buskies and E Vjaters",

year = "2022",

month = may,

day = "14",

language = "English",

volume = "207",

pages = "E455--E455",

journal = "Journal of Urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "5 S",

note = "Annual American Urological Association (AUA) Meeting , AUA 2022 ; Conference date: 13-05-2022 Through 16-05-2022",

url = "https://www.auanet.org/aua2022, https://www.aua2021.org/attendee-info/aua2022-dates-and-location?AUAID=, https://www.eventscribe.net/2022/AUA2022/",

}

Jones, RH, Fizazi, K, James, ND, Tammela, TL, Matsubara, N, Priou, F, Beuzeboc, P, Lesimple, T, Bono, P, Kataja, V, Garcia, JA, Protheroe, A, Aspegren, J, Joensuu, H, Kuss, I, Thiele, S, Fiala-Buskies, S & Vjaters, E 2022, 'Long-term Safety of Darolutamide Among Patients with Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy', Journal of Urology, vol. 207, no. 5 S, MP27-13, pp. E455-E455. <https://www.auajournals.org/action/doSearch?AllField=Long-term+Safety+of+Darolutamide+Among+Patients+with+Metastatic+Castration-resistant+Prostate+Cancer+Who+Received+More+Than+4+Years+of+Therapy&ContentGroupKey=10.1016%2Fjuro.2022.207.issue-Supplement_5>

TY - JOUR

T1 - Long-term Safety of Darolutamide Among Patients with Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy

AU - Jones, RH

AU - Fizazi, K

AU - James, ND

AU - Tammela, TL

AU - Matsubara, N

AU - Priou, F

AU - Beuzeboc, P

AU - Lesimple, T

AU - Bono, P

AU - Kataja, V

AU - Garcia, JA

AU - Protheroe, A

AU - Aspegren, J

AU - Joensuu, H

AU - Kuss, I

AU - Thiele, S

AU - Fiala-Buskies, S

AU - Vjaters, E

PY - 2022/5/14

Y1 - 2022/5/14

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:000836935504063&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0022-5347

VL - 207

SP - E455-E455

JO - Journal of Urology

JF - Journal of Urology

IS - 5 S

M1 - MP27-13

T2 - Annual American Urological Association (AUA) Meeting

Y2 - 13 May 2022 through 16 May 2022

ER -

Long-term Safety of Darolutamide Among Patients with Metastatic Castration-resistant Prostate Cancer Who Received More Than 4 Years of Therapy

Field of Science*

Publication Type*

UN SDGs

Access to Document

Other files and links

Cite this